In a 24-h MTT assay, geraniin reduced HeLa and Jurkat cell viability, with reported IC50 values of 5.1±0.2 µM and 0.76±0.1 µM, respectively. PHA-stimulated human PBMC showed much smaller viability reductions over the tested range, although high-concentration effects were observed. This cell comparison does not establish clinical efficacy or general safety. [1]
Inhibition of recombinant Hsp90α ATPase
Biochemical assay · Recombinant human Hsp90α [1]
Geraniin reduced ATPase activity in a concentration-dependent manner. 17-AAG was the positive comparator and hardwickiic acid (HA) the negative comparator; activity was normalized to untreated enzyme.
Literature-Reported Treatment Conditions
- Treatment concentration
- 2, 10 and 50 µM (Figure 3A)
- Exposure duration
- 60 min
- Method
- ATP hydrolysis assay at 40°C with 40 nM Hsp90α and 100 µM ATP; ADP Hunter Plus fluorescence readout
- Reported limits
- Final solvent content for this ATPase assay is not specified in the read assay subsection; no numerical IC50 was reported there or in Figure 3A.
Methods and source locations
Compound reported in the paper: Geraniin; Compound label in the paper: Compound 54
Literature on geraniin; does not establish activity, purity or stability of an Adooq lot.
Materials: ATP Hydrolysis Inhibition; Results: Inhibition of Hsp90α by Geraniin; Figure 3A and caption
Residual Hsp90α ATPase activity relative to untreated enzyme: Fluorescence measurement of ADP generation; untreated enzyme set to 100%; background lacking enzyme or substrate subtracted — Figure 3A and caption; ATP Hydrolysis Inhibition
Geraniin effects on HeLa, Jurkat and PBMC viability
Cell-based study · HeLa epithelial carcinoma cells, Jurkat leukemia cells and PHA-stimulated human peripheral blood mononuclear cells (PBMC) [1]
After 24 h, geraniin reduced the MTT viability endpoint in HeLa and Jurkat cells. PBMC were less affected over the tested range; this comparator does not establish general safety.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5–50 µM geraniin
- Exposure duration
- 24 h
- Method
- Cell exposure followed by MTT conversion assay; trypan-blue exclusion described as an additional viability assessment
- Vehicle
- 0.10% (v/v) DMSO; vehicle-treated cells are the survival reference
- Co-treatment
- None; 17-AAG tested separately as comparator
- Reported limits
- Cellular geraniin stability/metabolite composition not established in this experiment; ± values are reproduced as reported, with general statistical reporting as mean ± SD, without assuming independent donor n.
Methods and source locations
Compound reported in the paper: Geraniin; Compound label in the paper: Compound 54
Literature on geraniin; does not establish activity, purity or stability of an Adooq lot.
Cell Culture and Treatment; Cell Proliferation and Viability; Results: Effect of Geraniin on Cancer Cell Viability; Figure 5A and caption
HeLa viability after geraniin exposure: 24-h MTT viability dose-response relative to 0.10% DMSO control — Results: Effect of Geraniin on Cancer Cell Viability; Figure 5A; Cell Proliferation and Viability
Jurkat viability after geraniin exposure: 24-h MTT viability dose-response relative to 0.10% DMSO control — Results: Effect of Geraniin on Cancer Cell Viability; Figure 5A; Cell Proliferation and Viability
PHA-stimulated PBMC viability comparator: Figure 5A comparison; Results additionally describe minimal high-dose cytotoxic effects by trypan-blue exclusion — Figure 5A; Results: Effect of Geraniin on Cancer Cell Viability